Next Article in Journal
A TAT Peptide-Functionalized Liposome Delivery Phage System (TAT-Lip@PHM) for an Enhanced Eradication of Intracellular MRSA
Previous Article in Journal
Linking TLR-7 Signaling to Downregulation of Placental P-Glycoprotein: Implications for Fetal Drug Exposure
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Editorial

Expanding the Toolbox of Biomedical HIV Prevention Options Through Innovative Design

by
J. Gerardo García-Lerma
Laboratory Branch, Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA
Pharmaceutics 2025, 17(6), 742; https://doi.org/10.3390/pharmaceutics17060742
Submission received: 23 April 2025 / Accepted: 8 May 2025 / Published: 5 June 2025
Research on biomedical HIV prevention has shown that no single product can meet the needs and preferences of all individuals [1]. Despite the increasing availability of options for HIV pre-exposure prophylaxis (PrEP), overall coverage remains suboptimal [2]. Daily oral pre-exposure prophylaxis (PrEP) with emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF) is highly effective, yet adherence to a daily pill poses challenges for some individuals [3]. Long-acting injectable drug formulations such as cabotegravir (CAB) and lenacapavir can help address adherence challenges and offer a discreet option with extended dosing intervals. However, the frequency of injections and required clinical visits may deter some users [4]. For women, a 1-month intravaginal ring delivering dapivirine provides an alternative PrEP method. Nevertheless, preferences for rings vary across age groups and settings [5,6]. An on-demand PrEP option with FTC/TDF is available for men who have sex with men, offering a suitable option for individuals with infrequent, unplanned sexual activity or those who prefer not to use daily or injectable PrEP [7,8]. However, this approach follows a complex 2-1-1 schedule, requiring two FTC/TDF pills before sex, followed by one pill at 24 h and another at 48 h post-sex, which can be challenging to maintain.
This Special Issue of Pharmaceutics, “HIV/AIDS Prevention Formulation Design and Optimization and Its Pharmacokinetic-Pharmacodynamic Evaluation” (https://www.mdpi.com/journal/pharmaceutics/special_issues/1STR546UJF, accessed on 18 April 2025), highlights several innovative strategies for delivering PrEP and expanding the toolbox of available options. Several studies focus on long-acting or ultra-long-acting PrEP, including monoclonal antibodies and new drug formulations and delivery methods. As highlighted in a review article by Nayan et al., (contribution 1) ideal candidates for long-acting PrEP should consider key attributes including long dosing intervals, a short pharmacokinetic (PK) tail after treatment discontinuation, and factors such as cost, storage, and transportation requirements. Curley et al. (contribution 2) describe a semi-solid prodrug nanoparticle formulation of FTC, highlighting how this strategy has the potential to extend the half-life of water-soluble drugs and increase the availability of long-acting products. In two related studies, Kinsale et al. (contribution 3) and Daly et al. (contribution 4) explore reservoir-style poly (ɛ-caprolactone) biodegradable implants for the delivery of islatravir either alone or in combination with the hormonal contraceptive etonogestrel. This multipurpose prevention technology could offer women dual protection in a single product, addressing reproductive health concerns while promoting PrEP uptake. Young et al. (contribution 5) characterize the pharmacokinetics, biodegradation, and removability of poly(lactic-co-glycolic acid)-based in situ forming implants (ISFIs) containing CAB. In early preclinical studies, ISFIs were well tolerated, provided ultra-long-acting protection against repeated simian HIV (SHIV) exposure in macaques, and could be co-formulated with hormonal contraceptives for broader prevention benefits [9,10]. Mayer et al. (contribution 6) report on the PK of broadly neutralizing monoclonal antibodies (mAb) that incorporate LS mutations (M428L/N434S) in the Fc region to extend the durability for PrEP or treatment. Using population PK models and data from 16 clinical trials with 5 different LS and parental versions of mAbs, they show how the LS mutations improve PK by increasing elimination half-life, area under the curve value, and serum concentrations. These characteristics may offer extended durability for PrEP or treatment, potentially reducing dosing frequency.
Approaches that rely on more frequent dosing or on-demand use are also discussed in this Special Issue. Kinvig et al. (contribution 7) and Vora et al. (contribution 8) highlight the promise of microarray patches (MAPs) to deliver HIV PrEP or treatment. MAPs present a promising drug delivery platform that is user-friendly and suitable for self-administration. Kinvig et al. (contribution 7) use physiologically based pharmacokinetic modeling to investigate the PK of MAPs delivering CAB, defining optimal dosing strategies to maintain plasma CAB concentrations above protective thresholds for a week. Vora et al. (contribution 8) address the complexity of drug delivery via MAPs, emphasizing the importance of considering both microneedle designs and drug formulations to achieve effective delivery of CAB or other antiretroviral drugs. While questions remain regarding the required patch size to deliver appropriate CAB concentrations, these studies set the stage for new patch designs that may leverage more potent drugs requiring lower loading doses. An article by Peet et al. (contribution 9) highlights the potential of topical inserts—small, tablet-like products that can be discreetly packaged and used on demand for rectal and vaginal protection against HIV. Discreet design and portability may help increase accessibility and user preference. In preclinical studies, inserts containing TAF and elvitegravir were safe, effective, and versatile, offering potential for both pre- and post-exposure application.
Given the dynamic nature of individual preferences and circumstances, continued development of new PrEP options is essential to achieve global HIV prevention targets. Studies such as the ones described in this Special Issue of Pharmaceutics may help prioritize products that have the highest potential for clinical advancement, expand the range of available methods, and ultimately enhance overall PrEP uptake.

Funding

CDC intramural funding.

Conflicts of Interest

J.G.G.-L. is named in a US Government (USG) patent on “HIV post-exposure prophylaxis” and a patent application on “HIV pre-exposure prophylaxis”.

List of Contributions

  • Nayan, M.U.; Panja, S.; Sultana, A.; Zaman, L.A.; Vora, L.K.; Sillman, B.; Gendelman, H.E.; Edagwa, B. Polymer Delivery Systems for Long-Acting Antiretroviral Drugs. Pharmaceutics 2024, 16, 183. https://doi.org/10.3390/pharmaceutics16020183.
  • Curley, P.; Hobson, J.J.; Liptrott, N.J.; Makarov, E.; Al-Khouja, A.; Tatham, L.; David, C.A.W.; Box, H.; Neary, M.; Sharp, J.; et al. Preclinical Evaluation of Long-Acting Emtricitabine Semi-Solid Prodrug Nanoparticle Formulations. Pharmaceutics 2023, 15, 1835. https://doi.org/10.3390/pharmaceutics15071835.
  • Kinsale, T.S.; Cottrell, M.L.; Li, L.; Brand, R.; Gatto, G.; Luecke, E.; Norton, C.; Krovi, A.; Dumond, J.B.; Rao, G.; et al. Pharmacokinetic Modeling to Guide Preclinical Development of an Islatravir-Eluting Reservoir-Style Biodegradable Implant for Long-Acting HIV PrEP. Pharmaceutics 2024, 16, 201. https://doi.org/10.3390/pharmaceutics16020201.
  • Daly, M.B.; Wong-Sam, A.; Li, L.; Krovi, A.; Gatto, G.J.; Norton, C.; Luecke, E.H.; Mrotz, V.; Forero, C.; Cottrell, M.L.; et al. Pharmacokinetic Study of Islatravir and Etonogestrel Implants in Macaques. Pharmaceutics 2023, 15, 2676. https://doi.org/10.3390/pharmaceutics15122676.
  • Young, I.C.; Thorson, A.L.; Shrivastava, R.; Sykes, C.; Schauer, A.P.; Cottrell, M.L.; Kashuba, A.D.M.; Benhabbour, S.R. Dose-Ranging Plasma and Genital Tissue Pharmacokinetics and Biodegradation of Ultra-Long-Acting Cabotegravir In Situ Forming Implant. Pharmaceutics 2023, 15, 1487. https://doi.org/10.3390/pharmaceutics15051487.
  • Mayer, B.T.Z.L.; de Camp, A.C.; Yu, C.; Sato, A.; Angier, H.; Seaton, K.E.; Yates, N.; Ledgerwood, J.E.; Mayer, K.; Caskey, M.; et al. Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV. Pharmaceutics 2024, 16, 594. https://doi.org/10.3390/pharmaceutics16050594.
  • Kinvig, H.; Rajoli, R.K.R.; Pertinez, H.; Vora, L.K.; Volpe-Zanutto, F.; Donnelly, R.F.; Rannard, S.; Flexner, C.; Siccardi, M.; Owen, A. Physiologically Based Pharmacokinetic Modelling of Cabotegravir Microarray Patches in Rats and Humans. Pharmaceutics 2023, 15, 2709. https://doi.org/10.3390/pharmaceutics15122709.
  • Vora, L.K.; Tekko, I.A.; Zanutto, F.V.; Sabri, A.; Choy, R.K.M.; Mistilis, J.; Kwarteng, P.; Jarrahian, C.; McCarthy, H.O.; Donnelly, R.F. A Bilayer Microarray Patch (MAP) for HIV Pre-Exposure Prophylaxis: The Role of MAP Designs and Formulation Composition in Enhancing Long-Acting Drug Delivery. Pharmaceutics 2024, 16, 142. https://doi.org/10.3390/pharmaceutics16010142.
  • Peet, M.M.; Agrahari, V.; Clark, M.R.; Doncel, G.F. Preclinical and Early Clinical Development of Tenofovir Alafenamide/Elvitegravir Topical Inserts for Effective On-Demand Vaginal and Rectal HIV Prevention. Pharmaceutics 2024, 16, 348. https://doi.org/10.3390/pharmaceutics16030348.

References

  1. Wulandari, L.P.L.; He, S.Y.; Fairley, C.K.; Bavinton, B.R.; Marie-Schmidt, H.; Wiseman, V.; Guy, R.; Tang, W.; Zhang, L.; Ong, J.J. Preferences for pre-exposure prophylaxis for HIV: A systematic review of discrete choice experiments. EClinicalMedicine 2022, 51, 101507. [Google Scholar] [CrossRef] [PubMed]
  2. AVAC. 2025. Available online: https://data.prepwatch.org/ (accessed on 18 April 2025).
  3. Zhang, J.; Li, C.; Xu, J.; Hu, Z.; Rutstein, S.E.; Tucker, J.D.; Ong, J.J.; Jiang, Y.; Geng, W.; Wright, S.T.; et al. Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: A global systematic review and meta-analysis. Lancet HIV 2022, 9, e254–e268. [Google Scholar] [CrossRef] [PubMed]
  4. Rogers, B.G.; Chan, P.A.; Sutten-Coats, C.; Zanowick-Marr, A.; Patel, R.R.; Mena, L.; Goedel, W.C.; Chu, C.; Silva, E.; Galipeau, D.; et al. Perspectives on long-acting formulations of pre-exposure prophylaxis (PrEP) among men who have sex with men who are non-adherent to daily oral PrEP in the United States. BMC Public Health 2023, 23, 1643. [Google Scholar] [CrossRef] [PubMed]
  5. Nair, G.; Celum, C.; Szydlo, D.; Brown, E.R.; Akello, C.A.; Nakalega, R.; Macdonald, P.; Milan, G.; Palanee-Phillips, T.; Reddy, K.; et al. Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: A randomised, open-label, crossover trial. Lancet HIV 2023, 10, e779–e789. [Google Scholar] [CrossRef] [PubMed]
  6. Griffin, J.B.; Ridgeway, K.; Montgomery, E.; Torjesen, K.; Clark, R.; Peterson, J.; Baggaley, R.; van der Straten, A. Vaginal ring acceptability and related preferences among women in low- and middle-income countries: A systematic review and narrative synthesis. PLoS ONE 2019, 14, e0224898. [Google Scholar] [CrossRef] [PubMed]
  7. Molina, J.M.; Ghosn, J.; Assoumou, L.; Delaugerre, C.; Algarte-Genin, M.; Pialoux, G.; Katlama, C.; Slama, L.; Liegeon, G.; Beniguel, L.; et al. Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): A prospective observational cohort study. Lancet HIV 2022, 9, e554–e562. [Google Scholar] [CrossRef] [PubMed]
  8. Molina, J.M.; Capitant, C.; Spire, B.; Pialoux, G.; Cotte, L.; Charreau, I.; Tremblay, C.; Le Gall, J.M.; Cua, E.; Pasquet, A.; et al. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N. Engl. J. Med. 2015, 373, 2237–2246. [Google Scholar] [CrossRef] [PubMed]
  9. Young, I.C.; Massud, I.; Cottrell, M.L.; Shrivastava, R.; Maturavongsadit, P.; Prasher, A.; Wong-Sam, A.; Dinh, C.; Edwards, T.; Mrotz, V.; et al. Ultra-long-acting in-situ forming implants with cabotegravir protect female macaques against rectal SHIV infection. Nat. Commun. 2023, 14, 708. [Google Scholar] [CrossRef] [PubMed]
  10. Young, I.C.; Pallerla, A.; Cottrell, M.L.; Maturavongsadit, P.; Prasher, A.; Shrivastava, R.; De la Cruz, G.; Montgomery, S.A.; Schauer, A.; Sykes, C.; et al. Long-acting injectable multipurpose prevention technology for prevention of HIV and unplanned pregnancy. J. Control. Release 2023, 363, 606–620. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

García-Lerma, J.G. Expanding the Toolbox of Biomedical HIV Prevention Options Through Innovative Design. Pharmaceutics 2025, 17, 742. https://doi.org/10.3390/pharmaceutics17060742

AMA Style

García-Lerma JG. Expanding the Toolbox of Biomedical HIV Prevention Options Through Innovative Design. Pharmaceutics. 2025; 17(6):742. https://doi.org/10.3390/pharmaceutics17060742

Chicago/Turabian Style

García-Lerma, J. Gerardo. 2025. "Expanding the Toolbox of Biomedical HIV Prevention Options Through Innovative Design" Pharmaceutics 17, no. 6: 742. https://doi.org/10.3390/pharmaceutics17060742

APA Style

García-Lerma, J. G. (2025). Expanding the Toolbox of Biomedical HIV Prevention Options Through Innovative Design. Pharmaceutics, 17(6), 742. https://doi.org/10.3390/pharmaceutics17060742

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop